ArticleChemistry & biodiversity2026
Isolation of Metabolites With Antiviral Activity From the Brown Algae Dictyota fasciola and Dictyota mediterranea.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Marine-Derived Natural Products Against Flaviviruses: Mechanisms, Evidence, and Future Directions.Marine drugs · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Twenty diterpenes (1-20) and a sesquiterpene (21) were isolated from Dictyota fasciola and Dictyota mediterranea collected from the Aegean Sea and evaluated as potential antiviral agents against a panel of viral pathogens. Among the isolated metabolites, six dolabellane diterpenes (1-4, 9, and 12) and one germacrane sesquiterpene (21) are new natural products. The evaluation of the antiviral activity of the isolated compounds was carried out against three viruses of different phylogenetic backgrounds that are characterized by high incidence in human population and cause significant medical threat and economic losses worldwide: herpes simplex virus (HSV-1), human coronavirus (HCoV-NL63), and Zika virus (ZIKV). The antiviral assays demonstrated that some compounds inhibited the viruses within a concentration range of 3-10 µg/mL. The maximal suppression of viral replication was 90% for HSV-1, 99.99% for HCoV-NL63, and 96.8% for ZIKV, highlighting the differential efficacy of the tested compounds against specific viruses. Mechanistic studies revealed that, depending on the compound, antiviral activity occurred either at the virus attachment stage or during a post-entry replication stage. Among the tested compounds, metabolites 6-8, 13, 17, and 18 exhibited considerable antiviral activity against RNA (HCoV-NL63, ZIKV) and DNA (HSV-1) viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.